Pharmacokinetics/Pharmacodynamics symposium
Executive Summary
FDA Center for Drug Evaluation and Research Director Carl Peck, MD, emphasized the importance of performing pharmacokinetic and pharmacodynamic studies early in the drug development process to participants at an Oct. 12 conference cosponsored by Marion Labs, the National Center for Toxicological Research and the University of Maryland.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.